Llama Antibodies May Detect Cerebral Lesions Associated with Alzheimer’s

Summary: Researchers have developed a new, non invasive way to bypass the blood brain barrier and reach brain cells in mouse models of Alzheimer’s disease using two types of llama antibodies.

Source: Institut Pasteur.

The major challenge facing physicians treating Alzheimer’s is the ability to detect markers of the disease as early as possible. These markers, located in the brain, are difficult to access, hampering diagnosis. Using two types of llama antibody capable of crossing the blood-brain barrier, scientists from the Institut Pasteur, Inserm, the CNRS, the CEA, Pierre & Marie Curie and Paris Descartes Universities and Roche have developed a non-invasive approach to reach brain cells in a mouse model of the disease. Once in the brain, these llama antibodies can specifically mark and show amyloid plaques and neurofibrillary tangles, the two types of lesions that characterize Alzheimer’s disease. These results were published in the Journal of Controlled Release on October 7, 2016.

Alzheimer’s disease is characterized by two types of cerebral lesion: amyloid plaques and neurofibrillary tangles. Amyloid beta peptide (Aβ), naturally present in the brain, builds up over the years as a result of genetic and environmental factors until it forms amyloid plaques. This build-up is toxic for nerve cells: it leads to a loss of neuronal structure and to what is known as “neurofibrillary” tangles (abnormal aggregation of the tau protein), which in turn results in cell death.

In this study, the team led by Pierre Lafaye, Head of the Antibody Engineering Platform in the Citech at the Institut Pasteur, in collaboration with the Chemistry of Biomolecules and Integrative Neurobiology of Cholinergic Systems Units from the Institut Pasteur and the CNRS, developed two new types of antibody capable of detecting the extracellular and intracellular targets (respectively amyloid plaques and neurofibrillary tangles) that are characteristic of Alzheimer’s disease. To achieve this, they turned their attention to camelids, specifically llamas, since their small antibodies are easy to use. They used the variable region of the antibody, known as VHH or nanobodiesTM, to specifically recognize the markers of Alzheimer’s.

These antibodies have the rare ability to cross the blood-brain barrier, which generally protects the brain from microbial attacks but also prevents potential therapeutic molecules from reaching it.

This collaborative research project, jointly conducted by scientists from the Institut Pasteur, Inserm, the CNRS, the CEA, Pierre & Marie Curie and Paris Descartes Universities and the Roche Group, led to the development of anti-Aβ and anti-tau protein antibodies that specifically detect amyloid plaques and neurofibrillary tangles. These antibodies were subsequently tested in vitro on the brain tissue of Alzheimer’s patients.

Image shows the VHH antibodies.
The specific VHH antibody for plaques, labeled with a green fluorochrome, is injected into mice. The VHH travels along the blood vessels before marking the plaques in the brain. Photo taken using two-photon microscopy. NeuroscienceNews.com image is credited to Institut Pasteur.

The antibodies were then tested in vivo in two mouse models, each with one of the two characteristic lesions associated with Alzheimer’s disease. These antibodies, labeled with a green fluorochrome, were injected intravenously and crossed the blood-brain barrier, binding to the two targets the scientists were aiming to identify: amyloid plaques and neurofibrillary tangles. This made the signs of the disease visible in the brain using two-photon microscopy. The scientists involved in this collaborative project are currently working on the development of an MRI imaging technique to observe the lesions. In the long term this could be applied to humans.

“Being able to diagnose Alzheimer’s at an early stage could enable us to test treatments before the emergence of symptoms, something we were previously unable to do,” explained Pierre Lafaye. These VHH antibodies could be used in combination with therapeutic molecules so that the molecules can be delivered in a targeted way to the brain.

Patents have been filed for these VHH antibodies and for their use based on their ability to cross the blood-brain barrier and bind to amyloid plaques and tau proteins.

About this Alzheimer’s disease research article

Funding: This research was partly funded by the Roche Institute, the France Alzheimer Foundation and the Georges Pompidou Foundation.

Source: Myriam Rebeyrotte – Institut Pasteur
Image Source: This NeuroscienceNews.com image is credited to Institut Pasteur.
Original Research: Abstract for “Camelid single-domain antibodies: A versatile tool for in vivo imaging of extracellular and intracellular brain targets” by Tengfei Li, Matthias Vandesquille, Fani Koukouli, Clémence Dudeffant, Ihsen Youssef, Pascal Lenormand, Christelle Ganneau, Uwe Maskos, Christian Czech, Fiona Grueninger, Charles Duyckaerts, Marc Dhenain, Sylvie Bay, Benoît Delatour, and Pierre Lafaye in Journal of Controlled Release. Published online November 3 2016 doi:10.1016/j.jconrel.2016.09.019

Cite This NeuroscienceNews.com Article

[cbtabs][cbtab title=”MLA”]Institut Pasteur. “New Theory Debunks Idea That Math Abilities Are Inate.” NeuroscienceNews. NeuroscienceNews, 3 November 2016.
<https://neurosciencenews.com/alzheimers-llama-antibodies-lesions-5426/>.[/cbtab][cbtab title=”APA”]Institut Pasteur. (2016, November 3). New Theory Debunks Idea That Math Abilities Are Inate. NeuroscienceNews. Retrieved November 3, 2016 from https://neurosciencenews.com/alzheimers-llama-antibodies-lesions-5426/[/cbtab][cbtab title=”Chicago”]Institut Pasteur. “New Theory Debunks Idea That Math Abilities Are Inate.” https://neurosciencenews.com/alzheimers-llama-antibodies-lesions-5426/ (accessed November 3, 2016).[/cbtab][/cbtabs]


Abstract

Camelid single-domain antibodies: A versatile tool for in vivo imaging of extracellular and intracellular brain targets

Detection of intracerebral targets with imaging probes is challenging due to the non-permissive nature of blood-brain barrier (BBB). The present work describes two novel single-domain antibodies (VHHs or nanobodies) that specifically recognize extracellular amyloid deposits and intracellular tau neurofibrillary tangles, the two core lesions of Alzheimer’s disease (AD). Following intravenous administration in transgenic mouse models of AD, in vivo real-time two-photon microscopy showed gradual extravasation of the VHHs across the BBB, diffusion in the parenchyma and labeling of amyloid deposits and neurofibrillary tangles. Our results demonstrate that VHHs can be used as specific BBB-permeable probes for both extracellular and intracellular brain targets and suggest new avenues for therapeutic and diagnostic applications in neurology.

“Camelid single-domain antibodies: A versatile tool for in vivo imaging of extracellular and intracellular brain targets” by Tengfei Li, Matthias Vandesquille, Fani Koukouli, Clémence Dudeffant, Ihsen Youssef, Pascal Lenormand, Christelle Ganneau, Uwe Maskos, Christian Czech, Fiona Grueninger, Charles Duyckaerts, Marc Dhenain, Sylvie Bay, Benoît Delatour, and Pierre Lafaye in Journal of Controlled Release. Published online November 3 2016 doi:10.1016/j.jconrel.2016.09.019

Feel free to share this Neuroscience News.
Join our Newsletter
I agree to have my personal information transferred to AWeber for Neuroscience Newsletter ( more information )
Sign up to receive our recent neuroscience headlines and summaries sent to your email once a day, totally free.
We hate spam and only use your email to contact you about newsletters. You can cancel your subscription any time.